SkinBioTherapeutics (FRA:5KW) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is SkinBioTherapeutics Short-term investments?

Short-term investments only applies to insurance companies.

SkinBioTherapeutics Business Description

Other Exchanges SBTX:UK
Address Bath Lane, The Core, Newcastle Helix, Newcastle upon Tyne, GBR, NE4 5TF
SkinBioTherapeutics PLC is a UK-based life sciences company focused on skin health, developing products based on its proprietary SkinBiotix technology platform, which uses lysates of probiotic bacteria to strengthen the skin's natural barrier. The company's lead programmes target cosmetic skincare, the prevention of skin infections, and the treatment of eczema and other inflammatory skin conditions. It operates through a model of licensing its technology to commercial partners and developing its own branded consumer products, including through its subsidiary AxisBiotix, which sells a probiotic food supplement for people with psoriasis. SkinBioTherapeutics is headquartered in Newcastle upon Tyne and its shares trade on the AIM market of the London Stock Exchange. Revenue is generated primarily from licensing agreements, research collaborations, and direct-to-consumer sales of its supplement range, with its main markets in the United Kingdom and Europe.